Please assess the completion status of the following clinical trial:

Trial Title: Ascending Multi-dose Study of REGN727(SAR236553) With and Without Concomitant Atorvastatin

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 8.0

Eligibility Criteria:
Inclusion Criteria~* Men and women with elevated cholesterol on stable doses of atorvastatin 10-40mg/day regimen~* Body mass index between 18.0 and 35.0 kg/m2, inclusive~* For women of childbearing potential, a negative serum pregnancy test at the screening visit and a negative urine pregnancy test on day -2 or day -1~* For men and women of childbearing potential, willingness to utilize adequate contraception and not become pregnant (or have their partner\[s\] become pregnant)during the full duration of the study~* Willing, committed and able to return for all the clinic visits and complete all study-related procedures~* Able to read, and able to sign the informed consent form~Exclusion Criteria:~* History of MI, ACS, Angina, Stroke, peripheral vascular disease, or cardiac revascularization~* Pregnant or breast-feeding women~* Blood donation of any volume within 1 month prior to administration of study drug~* Congestive heart failure~* Consumption of greater than 1 quart of grapefruit juice per day~* Previous exposure to any therapeutic or investigational biological agent within 30 days of screening~* History of alcohol or drug abuse within one year to the screening visit~The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Group 1 with atorvastatin (Type: EXPERIMENTAL): Dose 1 versus placebo
- Group 2 with atorvastatin (Type: EXPERIMENTAL): Dose 1 versus placebo
- Group 3 with atorvastatin (Type: EXPERIMENTAL): Dose 2 versus placebo
- Group 4 with atorvastatin (Type: EXPERIMENTAL): Dose 2 versus placebo
- Group 5 with atorvastatin (Type: EXPERIMENTAL): Dose 3 versus placebo
- Group 6 with atorvastatin (Type: EXPERIMENTAL): Dose 3 versus placebo
- Group 7 without atorvastatin (Type: EXPERIMENTAL): Dose 3 versus placebo
- Group 8 with atorvastatin (Type: EXPERIMENTAL): Dose4 versus placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).